BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240605T130000
DTEND;TZID=America/New_York:20240605T140000
DTSTAMP:20260405T150342
CREATED:20240513T202047Z
LAST-MODIFIED:20240513T202047Z
UID:65965-1717592400-1717596000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Bayer - Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi®
DESCRIPTION:Date: Wednesday\, June 5\, 2024\nTime: 1:00pm – 2:00pm ET \n\n \nTOPIC:\nClinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® \nWEBINAR OVERVIEW: \n\nThis session includes key information about Jivi including\, safety and efficacy data from the clinical trials\, step-wise dosing and Jivi RWE Data from the 4th interim analysis of HEM-POWR\, a multinational\, open-label\, prospective\, non-interventional\, multicenter cohort study of Jivi.\nThere will also be a review of the Q2 2024 340B pricing for the Bayer Hemophilia A portfolio under the Hemophilia Alliance Contract.\n\nSPEAKER:\n\nDr. Vanessa K. Salinas-Lunas\nPediatric Hematology\nCenter for Inherited Blood Disorders \nSPEAKER’S BIO:\nN/A
URL:https://hemoalliance.org/alliance-events/a-webinar-from-bayer-clinical-review-of-the-jivi-protect-viii-trial-and-insights-from-hem-powr-a-real-world-evidence-rwe-study-of-jivi/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR